162 related articles for article (PubMed ID: 29233917)
21. Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells.
Liu N; Liu JT; Ji YY; Lu PP
J Cardiovasc Pharmacol; 2011 Mar; 57(3):348-56. PubMed ID: 21383592
[TBL] [Abstract][Full Text] [Related]
22. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
Abe M
Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
[TBL] [Abstract][Full Text] [Related]
23. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC
Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754
[TBL] [Abstract][Full Text] [Related]
24. MKK6-p38 MAPK signaling pathway enhances survival but not bone-resorbing activity of osteoclasts.
Yamashita T; Kobayashi Y; Mizoguchi T; Yamaki M; Miura T; Tanaka S; Udagawa N; Takahashi N
Biochem Biophys Res Commun; 2008 Jan; 365(2):252-7. PubMed ID: 17983595
[TBL] [Abstract][Full Text] [Related]
25. [Mechanisms of myeloma-induced bone disease].
Abe M
Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
[TBL] [Abstract][Full Text] [Related]
26. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells.
Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL
J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166
[TBL] [Abstract][Full Text] [Related]
27. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
28. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
29. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway.
Salvador JM; Mittelstadt PR; Belova GI; Fornace AJ; Ashwell JD
Nat Immunol; 2005 Apr; 6(4):396-402. PubMed ID: 15735649
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway:: an implication of CRP involvement in plaque destabilization.
Williams TN; Zhang CX; Game BA; He L; Huang Y
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):61-6. PubMed ID: 14592848
[TBL] [Abstract][Full Text] [Related]
31. Blockade of CD26 signaling inhibits human osteoclast development.
Nishida H; Suzuki H; Madokoro H; Hayashi M; Morimoto C; Sakamoto M; Yamada T
J Bone Miner Res; 2014 Nov; 29(11):2439-55. PubMed ID: 24821427
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
33. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells.
Cho HY; Lee SW
Cell Immunol; 2014; 289(1-2):27-35. PubMed ID: 24709011
[TBL] [Abstract][Full Text] [Related]
34. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
36. Piperine alleviates osteoclast formation through the p38/c-Fos/NFATc1 signaling axis.
Deepak V; Kruger MC; Joubert A; Coetzee M
Biofactors; 2015; 41(6):403-13. PubMed ID: 26627060
[TBL] [Abstract][Full Text] [Related]
37. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells.
Grevers LC; de Vries TJ; Everts V; Verbeek JS; van den Berg WB; van Lent PL
Ann Rheum Dis; 2013 Feb; 72(2):278-85. PubMed ID: 22918932
[TBL] [Abstract][Full Text] [Related]
38. IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.
Puthier D; Bataille R; Amiot M
Eur J Immunol; 1999 Dec; 29(12):3945-50. PubMed ID: 10602002
[TBL] [Abstract][Full Text] [Related]
39. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways.
Pandey MK; Kale VP; Song C; Sung SS; Sharma AK; Talamo G; Dovat S; Amin SG
Exp Hematol; 2014 Oct; 42(10):883-96. PubMed ID: 25034231
[TBL] [Abstract][Full Text] [Related]
40. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
